MC

500.6

+1.45%↑

NDA.FI

11.73

+0.43%↑

DIM

202.4

+1.05%↑

MC

500.6

+1.45%↑

NDA.FI

11.73

+0.43%↑

DIM

202.4

+1.05%↑

MC

500.6

+1.45%↑

NDA.FI

11.73

+0.43%↑

DIM

202.4

+1.05%↑

MC

500.6

+1.45%↑

NDA.FI

11.73

+0.43%↑

DIM

202.4

+1.05%↑

MC

500.6

+1.45%↑

NDA.FI

11.73

+0.43%↑

DIM

202.4

+1.05%↑

Search

Grifols SA

Open

SectorFinance

8.532 1.96

Overview

Share price change

24h

Current

Min

8.374

Max

8.538

Key metrics

By Trading Economics

Income

17M

69M

Sales

183M

2B

P/E

Sector Avg

36.313

20.525

EPS

0.101

Profit margin

3.491

Employees

23,833

EBITDA

57M

482M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+65.92% upside

Market Stats

By TradingEconomics

Market Cap

1.6B

5.2B

Previous open

6.57

Previous close

8.532

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Grifols SA Chart

Past performance is not a reliable indicator of future results.

Related News

2 Apr 2025, 17:19 UTC

Acquisitions, Mergers, Takeovers

Grifols in 'Very Preliminary Talks' With Brookfield Over Renewed Takeover Bid -- 2nd Update

2 Apr 2025, 13:02 UTC

Acquisitions, Mergers, Takeovers

Grifols, Brookfield Deny Takeover Talks After Report of Renewed Interest -- Update

2 Apr 2025, 10:13 UTC

Acquisitions, Mergers, Takeovers

Grifols Board Denies Media Reports Over Talks With Brookfield for Another Takeover Bid

8 Jul 2024, 10:40 UTC

Acquisitions, Mergers, Takeovers

Trending: Grifols Founding Family, Brookfield Eye Takeover Bid for Spanish Drugmaker

8 Jul 2024, 09:13 UTC

Acquisitions, Mergers, Takeovers

Grifols Faces Delisting Bid From Founding Family and Brookfield

15 Apr 2025, 09:55 UTC

Market Talk

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

2 Apr 2025, 09:27 UTC

Hot Stocks

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

Peer Comparison

Price change

Grifols SA Forecast

Price Target

By TipRanks

65.92% upside

12 Months Forecast

Average 14.02 EUR  65.92%

High 19.05 EUR

Low 11 EUR

Based on 3 Wall Street analysts offering 12 month price targets forGrifols SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

2

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

8.006 / 8.544Support & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Grifols SA

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.